17-Apr-2026
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Globe Newswire (Mon, 20-Apr 7:00 AM ET)
Globe Newswire (Mon, 6-Apr 7:00 AM ET)
Globe Newswire (Wed, 11-Mar 7:30 AM ET)
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Globe Newswire (Wed, 25-Feb 7:00 AM ET)
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Globe Newswire (Thu, 5-Feb 7:00 AM ET)
Market Chameleon (Tue, 3-Feb 6:08 AM ET)
Globe Newswire (Mon, 2-Feb 7:00 AM ET)
Market Chameleon (Thu, 29-Jan 2:07 AM ET)
PRNewswire (Thu, 29-Jan 6:00 AM ET)
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
Globe Newswire (Tue, 27-Jan 3:00 AM ET)
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Sagimet Biosciences - Series A trades on the NASDAQ stock market under the symbol SGMT.
As of April 17, 2026, SGMT stock price climbed to $6.47 with 590,126 million shares trading.
SGMT has a beta of 2.39, meaning it tends to be more sensitive to market movements. SGMT has a correlation of 0.13 to the broad based SPY ETF.
SGMT has a market cap of $210.83 million. This is considered a Small Cap stock.
Last quarter Sagimet Biosciences - Series A reported $0 in Revenue and -$.29 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.12.
The top ETF exchange traded funds that SGMT belongs to (by Net Assets): VTI, VXF, IBB, DFAS, IWC.
SGMT has outperformed the market in the last year with a price return of +192.8% while the SPY ETF gained +36.3%. SGMT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.4% and +21.6%, respectively, while the SPY returned +2.9% and +8.3%, respectively.
SGMT support price is $5.84 and resistance is $6.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMT shares will trade within this expected range on the day.